Tracking Cancer with Liquid Biopsies
A Flinders Foundation grant is enabling Flinders researchers to trial a new liquid biopsy sample in the hope it will give them a head start in tracking and monitoring tumours.
The ability to rapidly adapt and overcome the beneficial effects of medication is a characteristic that makes many forms of cancer so difficult to cure. When it comes to treating tumours, decisions on which medication to use are often guided by knowledge of the tumour’s biology. This information is gathered by performing a surgical biopsy of the tumour itself. While effective, the technique only provides the treatment team with a snapshot of the tumour at that point in time.
Now, researchers at Flinders are trialling a new, less invasive technique – the collection of liquid biopsy samples – which they hope will give them a head start in tracking and monitoring tumours.
“Since taking a blood sample is relatively safe, the value of liquid biopsies will be to enable biopsy-like information to be captured regularly over time, allowing the changes in the cancer to be monitored over time,” said Professor of Pharmacology Michael Sorich, based in the Flinders Centre for Innovation in Cancer. “With an earlier understanding of how the cancer changes, it will hopefully be possible to treat the cancer more effectively,” he said.
Michael said liquid biopsies have several advantages over their surgical counterparts.
“The advantage of a liquid biopsy is that obtaining a blood or urine sample is typically much safer, convenient and less costly than obtaining a surgical biopsy. Liquid biopsies may not replace surgical biopsies entirely but they will complement them by making it easier to track how cancers change and react to medication,” he said.
According to study co-lead Associate Professor Chris Karapetis, researchers are always investigating better ways of tailoring treatment to individual patients, tracking treatment progress and knowing when to adjust or change it.
“This information gleaned from the liquid biopsy may help us to better tailor the treatment to each patient so that benefits of cancer therapy are maximised,” Chris said.
For patients involved in this study, there will be no difference in the high quality of their standard of care.
“The only difference is that patients will be empowered by the knowledge that their cancer experience and biological samples will be used to research better ways to treat cancer and monitor cancer treatment in the future,” Michael said.
Oncology patients of Flinders Centre in Innovation in Cancer were invited to participate in the study.
Flinders Foundation provided seed funding for this research.
This story was originally published in Southern Health News.
A chat with... Flinders Medical Centre Neonatal Critical Care Nurse, Sue Salvemini
Flinders Medical Centre Neonatal Critical Care Nurse, Sue Salvemini has been at Flinders since 1988!
Thanks to you…we did it! A new ECMO Machine is on its way
Thanks to you…we did it!
Santos’ gift for epilepsy
For the past 27 years Janet Murphy’s nights have been sleepless and full of worry.
Comfy chairs for Flinders
A good, comfy chair means a lot to patients and their families at Flinders.
Ground-breaking research targeting brain cancer
Flinders University’s Associate Professor Simon Conn is carrying out ground-breaking research
$225,000 and a new world record!
Mix102.3 Breakfast duo Jodie & Soda’s mammoth 52-hour ferris wheel marathon
Developing new methods to detect Gastro
Flinders University Associate Professor Jill Carr is working to develop new methods to detect Norovirus – a common and highly infectious form of gastro.
Helping to improve the diets of young children
A Flinders Foundation Health Seed Grant is exploring whether a new phone-based app could play a role in helping to improve the diets of young children
PhD Scholarships awarded
Two of Flinders University’s brightest students are preparing to embark on exciting new research after being awarded PhD Scholarships
Thank you for helping to prevent bowel cancer
Dr Symonds was recently awarded a $880,000 grant from the National Health and Medical Research Council